Healthcare · Biotechnology
Price
$1.48
Market Cap
$3.3M
Employees
9
Beta
0.90
Avg Volume
3,758,975
CEO
Hyung Heon Kim
Business Description
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.20
Stock Price: $1.48
EPS (Diluted): -7.35
EPS (Diluted): -7.35
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.79
Stock Price: $1.48
Total Equity: $5.33M
Shares: 1,766,026
Total Equity: $5.33M
Shares: 1,766,026
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
0.79
Market Cap: $3.26M
Total Debt: $68,000
Cash: $10.28M
EBITDA: -$12.95M
Total Debt: $68,000
Cash: $10.28M
EBITDA: -$12.95M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$4.8M
Market Cap: $3.26M
Total Debt: $68,000
Cash: $10.28M
Total Debt: $68,000
Cash: $10.28M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.00
Stock Price: $1.48
Revenue: $0.00
Shares: 1,766,026
Revenue: $0.00
Shares: 1,766,026
EV/Sales (Total value vs revenue — works when P/E can't)
API0.00
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
0.0%
Gross Profit: -$19,000
Revenue: $0.00
Revenue: $0.00
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
0.0%
Operating Income: -$13.71M
Revenue: $0.00
Revenue: $0.00
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
0.0%
Net Income: -$12.97M
Revenue: $0.00
Revenue: $0.00
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-172.9%
Net Income: -$12.97M
Total Equity: $5.33M
Total Equity: $5.33M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-149.4%
Operating Income: -$13.71M
Tax Rate: 0.0%
Equity: $5.33M
Total Debt: $68,000
Cash: $10.28M
Tax Rate: 0.0%
Equity: $5.33M
Total Debt: $68,000
Cash: $10.28M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
1.93
Current Assets: $10.88M
Current Liabilities: $5.65M
Current Liabilities: $5.65M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.01
Short-Term Debt: $68,000
Long-Term Debt: $0.00
Total Debt: $68,000
Total Equity: $5.33M
Long-Term Debt: $0.00
Total Debt: $68,000
Total Equity: $5.33M
Rev/Share (Top-line per share)
Revenue / Shares Outstanding
—
Revenue: $0.00
Shares: 1,766,026
Shares: 1,766,026
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$3.02
Total Equity: $5.33M
Shares: 1,766,026
Shares: 1,766,026
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-8.89
Operating CF: -$15.70M
CapEx: -$2,000
Shares: 1,766,026
CapEx: -$2,000
Shares: 1,766,026
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $1.48
Stock Price: $1.48
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$12.97M
Net Income: -$12.97M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares MTVA against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 24, 2026 7:29am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $72,000 | $28,000 | $7,000 | $24,000 | $19,000 |
| Gross Profit | $-72,000 | $-28,000 | $-7,000 | $-24,000 | $-19,000 |
| Operating Expenses | $15.3M | $19.6M | $15.9M | $28.8M | $13.7M |
| Operating Income | -$15.3M | -$19.6M | -$15.9M | -$28.8M | -$13.7M |
| Net Income | -$15.3M | -$14.0M | -$12.5M | -$27.6M | -$13.0M |
| EBITDA | -$15.2M | -$11.8M | -$12.5M | -$27.6M | -$13.0M |
| EPS | $-1,742.40 | $-477.84 | $-27.06 | $-39.16 | $-7.35 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 24, 2026 7:29am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $16.4M | $33.4M | $22.4M | $16.0M | $10.3M |
| Total Current Assets | $16.6M | $33.5M | $22.5M | $16.1M | $10.9M |
| Total Assets | $16.8M | $33.5M | $22.8M | $16.3M | $69.1M |
| Current Liabilities | $2.2M | $11.8M | $6.0M | $8.3M | $5.6M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $2.2M | $11.8M | $6.1M | $8.3M | $63.8M |
| Total Equity | $14.6M | $21.8M | $16.7M | $7.9M | $5.3M |
| Retained Earnings | -$81.8M | -$95.8M | -$108.3M | -$135.9M | -$148.8M |
Cash Flow (Annual)
Last updated: Jun 24, 2026 7:29am (3d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.1M | -$11.7M | -$10.8M | -$24.7M | -$15.7M |
| Capital Expenditure | $-3,000 | $0 | $-50,000 | $-8,000 | $-2,000 |
| Free Cash Flow | -$15.1M | -$11.7M | -$10.8M | -$24.7M | -$15.7M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $6.3M | $17.0M | -$10.9M | -$6.4M | -$5.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 2:28pm (18h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| Net Income |
-$4.3M -$6.4M – -$2.1M
|
-$2.9M -$4.3M – -$1.6M
|
-$2.4M -$2.4M – -$2.4M
|
-$2.2M -$2.2M – -$2.2M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 24, 2026 7:29am (3d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | — | — | — | — |
| Gross Profit Growth | +61.1% | +75.0% | -242.9% | +20.8% |
| Operating Income Growth | -28.3% | +19.1% | -81.3% | +52.4% |
| Net Income Growth | +8.6% | +10.7% | -121.3% | +53.0% |
| EBITDA Growth | +22.8% | -6.0% | -121.2% | +53.0% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:30am (2h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-08 | Tursi James Patrick | A-Award | 17,186.00 | $0.00 | $0 |
| 2026-06-08 | STRICKLAND D GORDON | A-Award | 17,186.00 | $0.00 | $0 |
| 2026-06-08 | Salsbury Michael | A-Award | 17,186.00 | $0.00 | $0 |
| 2026-06-08 | GROVES JASON L | A-Award | 17,186.00 | $0.00 | $0 |
| 2026-06-08 | KOVEN ANDREW I | A-Award | 17,186.00 | $0.00 | $0 |
| 2026-06-08 | Glickman Mark A | A-Award | 17,186.00 | $0.00 | $0 |
| 2026-01-23 | Woodworth Marshall H | A-Award | 28,000.00 | $0.00 | $0 |
| 2026-01-23 | Kim Hyung Heon | A-Award | 32,000.00 | $0.00 | $0 |
| 2025-08-12 | Woodworth Marshall H | G-Gift | 14,200.00 | $0.00 | $0 |
| 2025-06-30 | Glickman Mark A | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | GROVES JASON L | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | Tursi James Patrick | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | STRICKLAND D GORDON | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | KOVEN ANDREW I | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-30 | Salsbury Michael | A-Award | 28,147.00 | $0.00 | $0 |
| 2025-06-04 | Woodworth Marshall H | P-Purchase | 14,200.00 | $0.70 | $9,940 |
| 2025-05-08 | DONG-A ST CO., LTD | P-Purchase | 4,647,887.00 | $0.71 | $3.3M |
| 2025-03-01 | Woodworth Marshall H | F-InKind | 3,417.00 | $1.46 | $4,989 |
| 2025-03-01 | Kim Hyung Heon | F-InKind | 2,795.00 | $1.46 | $4,081 |
| 2024-11-30 | Kim Hyung Heon | F-InKind | 2,867.00 | $2.55 | $7,311 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for MTVA — it's generated by the pipeline (
market-narrative step).
No community reviews yet for MTVA.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30